An approach to the treatment of pulmonary sarcoidosis with corticosteroids: The six phases of treatment

Chest

Volumn 115, Issue 4, 1999, Pages 1158-1165

  Judson, Marc A ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Corticosteroid; Natural history; Pulmonary sarcoidosis; Therapy

Indexed keywords

CORTICOSTEROID; METHYLPREDNISOLONE; PREDNISONE;

CORTICOSTEROID THERAPY; DOSE CALCULATION; DOSE RESPONSE; HUMAN; LUNG SARCOIDOSIS; MAINTENANCE THERAPY; PRIORITY JOURNAL; RELAPSE; REVIEW;

EID: 0032932816     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.115.4.1158     Document Type: Article

References (59)

1. 1 Neville E, Walker AN, James DG. Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients. Q J Med 1983; 208:525-533
2. 2 Sones M, Isreal HL. Course and prognosis of sarcoidosis. Am J Med 1960; 29:84-93
3. 3 Mana J, Salazar A, Manresa F. Clinical factors predicting persistence of activity in sarcoidosis: a multivariate analysis of 193 cases. Respiration 1994; 61:219-225
4. 4 Isreal HI, Karlin P, Menduke H. Factors affecting outcome of sarcoidosis. Ann NY Acad Sci 1986; 465:395-406
5. 5 Lynch JP, Kazerooni EA, Gay SE. Pulmonary sarcoidosis. Clin Chest Med 1997; 18:755-785
6. 6 Huang CT, Heurich AE, Sutton AL, et al. Mortality in sarcoidosis: a changing pattern of the causes of death. Eur J Respir Dis 1981; 62:231-238
7. 7 Tomlinson JR, Sahn SA. Aspergilloma in sarcoid and tuberculosis. Chest 1987; 92:505-508
8. 8 Pinkston P, Saltini C, Muller-Quernheim J, et al. Corticosteroid therapy suppresses spontaneous interleukin 2 release and spontaneous proliferation of lung T lymphocytes of patients with active pulmonary sarcoidosis. J Immunol 1987; 139:755-760
9. 9 Siltzbach LE. Effects of cortisone in sarcoidosis: a study of 13 patients. Am J Med 1952; 12:139-160
10. 10 Gibson GJ, Prescott RJ, Muers MF, et al. British Thoracic Society Sarcoidosis study: effects of long-term corticosteroid treatment. Thorax 1996; 51:238-247
11. 11 Winterbauer RH, Kirtland SH, Corley DE. Treatment with corticosteroids. Clin Chest Med 1997; 18:843-851
12. 12 Sharma OP. Pulmonary sarcoidosis and corticosteroids. Am Rev Respir Dis 1993; 147:1598-1600
13. 13 Romer FK. Presentation of sarcoidosis and outcome of pulmonary changes. Dan Med Bull 1982; 29:27-32
14. 14 Isreal HL, Fouts DW, Beggs RA. A controlled trial of prednisone treatment of sarcoidosis. Am Rev Respir Dis 1973; 107:609-614
15. 15 Zaki MH, Lyons HA, Leilop L, et al. Corticosteroid therapy in sarcoidosis. NY State J Med 1987; 87:496-499
16. 16 Eule H, Weinecke A, Roth I. The possible influence or corticosteroid therapy on the natural course of pulmonary sarcoidosis. Ann NY Acad Sci 1986; 465:695-701
17. 17 Seleroos O, Sellergren TL. Corticosteroid therapy of pulmonary sarcoidosis. Scand J Respir Dis 1979; 60:215-221
18. 18 Harkleroad LE, Young RL, Savage PJ, et al. Pulmonary sarcoidosis: long-term follow-up of the effects of steroid therapy. Chest 1982; 82:84-87
19. 19 Gottlieb JE, Israel HL, Steiner RM, et al. Outcome in sarcoidosis: the relationship of relapse to corticosteroid therapy. Chest 1997; 111:623-631
20. 20 Hunninghake GW, Gilbert S, Pueringer R, et al. Outcome of treatment for sarcoidosis. Am J Respir Crit Care Med 1994; 149:893-898
21. 21 Selroos O, Sellergren TL. Corticosteroid therapy of pulmonary sarcoidosis. Scand J Respir Dis 1979; 60:215-221
22. 22 Winterbauer RH, Hutchinson JF. Use of pulmonary function tests in the management of sarcoidosis. Chest 1980; 78:640-647
23. 23 Baumann MH, Strange C, Sahn SA. Do chest radiograph findings reflect the clinical course of patients with sarcoidosis during corticosteroid withdrawal? AJR Am J Roentgenol 1990; 154:481-485
24. 24 Thomas PD, Hunnihake GW. Current concepts of the pathogenesis of sarcoidosis. Am Rev Respir Dis 1987; 135:747-760
25. 25 Rohatgi PK, Ryan JW, Lindeman P. Value of serial measurement of serum angiotensin-converting enzyme in the management of sarcoidosis. Am J Med 1981; 70:44-50
26. 26 DeRemee RA, Rohrbach MS. Serum angiotensin-converting enzyme activity in evaluating the clinical course of sarcoidosis. Ann Intern Med 1980; 92:361-365
27. 27 Keogh BA, Hunninghake GW, Line BR, et al. The alveolitis of pulmonary sarcoidosis. Am Rev Respir Dis 1983; 128:256-265
28. 67gallium scintigraphy, serum ACE levels, chest roentgenography, and blood lymphocyte subpopulations. Chest 1982; 82:732-738
29. 29 Baughman RP, Fernandez M, Bosken CH, et al. Comparison of gallium-67 scanning, bronchoalveolar lavage, and serum angiotensin-converting enzyme levels in pulmonary sarcoidosis. Am Rev Respir Dis 1984; 129:676-681
30. 30 Ward K, O'Connor C, Odium G, et al. Prognostic value of bronchoalveolar lavage in sarcoidosis: the critical influence of disease presentation. Thorax 1989; 44:6-12
31. 31 Laviolette M, La Forge J, Tennina S, et al. Prognostic value of bronchoalveolar lavage lymphocyte count in recently diagnosed pulmonary sarcoidosis. Chest 1991; 100:380-384
32. 32 Buchalter S, App W, Jackson L, et al. Bronchoalveolar lavage cell analysis in sarcoidosis. Ann NY Acad Sci 1986; 465:678-684
33. 33 Wallaert B, Ramon P, Fournier E, et al. Bronchoalveolar lavage, serum angiotensin-converting enzyme, and gallium-67 scanning in extrathoracic sarcoidosis. Chest 1982; 82:553-555
34. 34 Schoenberger CI, Line BR, Keogh BA, et al. Lung inflammation in sarcoidosis: comparison of serum angiotensinconverting enzyme levels with bronchoalveolar lavage and gallium-67 scanning assessment of the T lymphocyte alveolitis. Thorax 1982; 37:19-25
35. 35 Teirstein AS, Krumholtz S. Assessment of serum angiotensinconverting enzyme as a marker of activity in sarcoidosis: a study of 31 patients with erythema nodosum. Mt Sinai J Med 1987; 54:144-146
36. 36 Nishimura K, Itoh H, Kitaichi M, et al. Pulmonary sarcoidosis: correlation of CT and histopathologic findings. Radiology 1993; 189:105-109
37. 1 in the non nectrotizing granulomas of pulmonary sarcoidosis. Am J Respir Crit Care Med 1994; 149:197-204
38. 38 Spratling L, Tenholder MF, Underwood GH, et al. Daily vs alternate day prednisone therapy for stage II sarcoidosis. Chest 1985; 88:687-690
39. 39 DeRemee RA. The present status of treatment of pulmonary sarcoidosis: a house divided. Chest 1977; 71:388-393
40. 40 Johns CJ, MacGregor MI, Zachary JB, et al. Extended experience in the long-term corticosteroid treatment of pulmonary sarcoidosis. Ann NY Acad Sci 1976; 278:722-731
41. 41 Johns CJ, Schonfeld SA, Scott PP, et al. Longitudinal study of chronic sarcoidosis with low-dose maintenance corticosteroids. Ann NY Acad Sci 1986; 465:702-712
42. 42 Baughman RP, Lower EE, Lynch JP. Treatment modalities for sarcoidosis. Clin Pulm Med 1994; 1:223-231
43. 43 Baughman RP, Lower EE. Steroid sparing alternative treatments for sarcoidosis. Clin Chest Med 1997; 18:853-864
44. 44 Baughman RP, Lower EE. The effect of corticosteroid or methotrexate therapy on lung lymphocytes and macrophages in sarcoidosis. Am Rev Respir Dis 1990; 142:1268-1271
45. 45 Lower EE, Baughman RP. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med 1995; 155:846-851
46. 46 Sharma O, Hughes DTD, James DG, et al. Immunosuppressive therapy with azathioprine in sarcoidosis: Fifth International Conference on Sarcoidosis. Prague: Universita Karlova, 1971; 635-637
47. 47 Pacheco Y, Marechal C, Marechal F, et al. Azathioprine treatment of chronic pulmonary sarcoidosis. Sarcoidosis 1985; 2:107-113
48. 48 Zabel P, Entzian P, Dalhoff K, et al. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med 1997; 155:1665-1669
49. 49 Kataria YP. Chlorambucil in sarcoidosis. Chest 1980; 78: 36-43
50. 50 Israel HL, McComb BL. Chlorambucil treatment of sarcoidosis. Sarcoidosis 1991; 8:35-41
51. 51 Jones E, Cagen JP. Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas. Am Acad Dermatol 1990; 23:487-489
52. 52 Spiteri MA, Newman SP, Clarke SW, et al. Inhaled corticosteroids can modulate the immunopathogenesis of pulmonary sarcoidosis. Eur Respir J 1989; 2:218-224
53. 53 Selroos O, Lofroos A, Pietinalho A, et al. Inhaled budesonide for maintenance treatment of pulmonary sarcoidosis. Sarcoidosis 1994; 11:126-131
54. 54 Selroos O. Use of budesonide in the treatment of pulmonary sarcoidosis. Ann NY Acad Sci 1986; 465:713-721
55. 55 Pietinalho A. Inhaled corticosteroid therapy in pulmonary sarcoidosis. Sarcoidosis 1991; 8:168-169
56. 56 Alberts C, Van der Mark TW, Jansen HM, et al. Inhaled budesonide in pulmonary sarcoidosis: a double-gling, placebo-controlled study. Eur Respir J 1995; 8:682-688
57. 57 Zych D, Pawlicka L, Zielinski J. Inhaled budesonide vs prednisone in the maintenance treatment of pulmonary sarcoidosis. Sarcoidosis 1993; 10:56-61
58. 58 Gupta SK. Treatment of sarcoidosis patients by steroid aerosol: a 10-year prospective study from eastern India. Sarcoidosis 1989; 6:51-54
59. 59 Milman N, Graudal N, Grode G, et al. No effect of high dose inhaled steroids in pulmonary sarcoidosis: a double-blind, placebo-controlled study. J Intern Med 1994; 236:285-290